About Abliva
Abliva is a Healthcare company based in Lund (Sweden) founded in 2000, and was acquired by Pharming Group in February 2025. Drugs are developed to treat multiple neurological disorders. Abliva offers products and services including KL1333 and NV354. Its focus areas include Life Sciences, Neurology, Drugs and Neurodevelopmental Disorders. Its legal entity is ABLIVA, INC.
Company details
Abliva was founded in 2000 in Lund, Sweden, within the biotechnology sector focused on neurological treatments. Drug candidates such as KL1333, an NAD regulator, are advanced for chronic primary mitochondrial diseases including MELAS-MIDD and PEO-KSS spectrum disorders. NVP025 is targeted at mitochondrial myopathies, while NeuroSTAT addresses traumatic brain injury. Additional candidates like NV354 are under development for related conditions.
- Headquarters Lund, Sweden
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website abliva.com
- Social LinkedIn YouTube
- Acquired by Pharming Group (Feb 2025)
- Legal Name Abliva, Inc.
- Latest Funding Round$20.45M (USD), Post-IPO
Jun 2022
- InvestorsPharming Group
& 4 more
- Acquired byPharming Group
(Feb 2025)
Products & Services of Abliva
Abliva offers a comprehensive portfolio of products and services, including KL1333 and NV354.
Drug candidate for treating primary mitochondrial diseases.
Potential treatment for mitochondrial disease symptoms.
Apps and channels of Abliva
its YouTube channel Abliva AB has 179 subscribers and 30 videos.
Videos from Abliva
The most watched videos on Abliva's YouTube channel, Abliva AB (179 subscribers). Click a video to play it here.
More on Abliva AB.
Funding Insights of Abliva
- Total Rounds 2
- Last Round Post-IPO — $20.45M
- First Round $2.98M
(Mar 2019)
- Investors Count 4
All 2 funding rounds of Abliva with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | $20.45M | Post-IPO | – | – | |
| Mar 2019 | $2.98M | Post-IPO | – | – |
5 investors in total: 5 institutional.
Investors in Abliva
Abliva has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Pharming Group, IP Group and Hadean Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital and advisory services are offered across multiple sectors. | 2001 | ipgroupplc.com | London, United Kingdom | |
| hadeanventures.com | ||||
Offers pension schemes, insurance products, and loans through employer-based programs. | 2000 | opf.no | Oslo, Norway | |
Operates as a single-family office specializing in healthcare sector investments. | 2013 | nyip.nl | Amsterdam, Netherlands | |
Recombinant protein-based therapeutics for rare diseases are developed. | 1988 | pharming.com | Leiden, Netherlands |
Investor details for Abliva
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Abliva
12 people are tracked at Abliva (4 in leadership, 5 in board & advisors, 3 in team).
| Name | Role | Group |
|---|---|---|
Magnus Hansson | Executive Medical Director And Global Program Lead | Leadership |
Ellen K. Donnelly | CEO | Leadership |
Catharina Jz. Johansson | Deputy CEO, CFO & VP, Investor Relations | Leadership |
Eskil Elmér | CSO & VP, Discovery | Leadership |
Denise Goode | Director | Board & advisors |
David Laskow-Pooley | Chairman | Board & advisors |
David Bejker | Director | Board & advisors |
Roger Franklin | Director | Board & advisors |
Jan Törnell | Director | Board & advisors |
Imen Chamkha | Post-doc Researcher | Team |
Sonia Simón Serrano | Research Manager | Team |
Eleonor Åsander Frostner | Communications Officer & Lab Manager | Team |
Complete people profiles for Abliva
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Abliva
5 dated milestones of Abliva across 25 years, from founding to its latest funding, stage changes and deals.
- Founded Abliva is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.0M.
- Funding Latest funding round, Post-IPO, of $20.4M.
- Exit Acquired by Pharming Group.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Abliva
Complete news archive for Abliva
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abliva
Abliva was founded in 2000 and raised its 1st funding round 19 years after it was founded.
Abliva is headquartered in Lund, Sweden.
Abliva was founded in 2000 in Lund, Sweden, within the biotechnology sector focused on neurological treatments. Drug candidates such as KL1333, an NAD regulator, are advanced for chronic primary mitochondrial diseases including MELAS-MIDD and PEO-KSS spectrum disorders. NVP025 is targeted at mitochondrial myopathies, while NeuroSTAT addresses traumatic brain injury. Additional candidates like NV354 are under development for related conditions.
Abliva offers KL1333 and NV354.
Abliva has 5 investors. Key investors include Pharming Group, IP Group, Hadean Ventures, Oslo Pensjonsforsikring, and NYIP.
Abliva operates through Abliva, Inc..
Yes. Abliva was acquired by Pharming Group in February 2025.